Erectile dysfunction （ED） is a major complication of diabetes mellitus. Icariin has been shown to enhance erectile function through its bioactive form, icarisid Ih This study investigates the effects of icarisid Ⅱ ...Erectile dysfunction （ED） is a major complication of diabetes mellitus. Icariin has been shown to enhance erectile function through its bioactive form, icarisid Ih This study investigates the effects of icarisid Ⅱ on diabetic rats with ED and its potential mechanism viathe assessment of advanced glycosylation end products （AGEs）, autophagy, mTOR and the NO-cGMP pathway. Icarisid Ⅱ was extracted from icariin by an enzymatic method. In the control and diabetic ED groups, rats were administered normal saline; in the icarisid Ⅱ group, rats were administered icarisid Ⅱ intragastrically. Erectile function was evaluated by measuring intracavernosal pressure/mean arterial pressure （ICP/MAP）. AGE concentrations, nitric oxide synthase （NOS） activity and cGMP concentration were assessed by enzyme immunoassay. Cell proliferation was analysed using methyl thiazolyl tetrazolium assay and flow cytometry. Autophagosomes were observed by transmission electron microscopy, monodansylcadaverine staining and GFP-LC3 Iocalisation. The expression of NOS isoforms and key proteins in autophagy were examined by western blot. Our results have shown that Icarisid Ⅱ increased ICP/MAP values, the smooth muscle cell （SMC） growth curve, S phase and SMC/collagen fibril （SMC/CF） proportions and decreased Beclin 1 （P〈0.05）. Icarisid Ⅱ significantly increased the proliferative index and p-p70S6K（Thr389） levels and decreased the numbers of autophagosomes and the levels of LC3-11 （P〈0.01）. Icarisid Ⅱ decreased AGE concentrations and increased cGMP concentration, NOS activity （P〈0.05） and cNOS levels （P〈0.01） in the diabetic ED group. Therefore, Icarisid Ⅱ constitutes a promising compound for diabetic ED and might be involved in the upregulation of SMC proliferation and the NO-cGMP pathway and the downregulation of AGEs, autophagy and the mTOR pathway.展开更多
目的探讨七氟醚后处理对犬体外循环肺缺血/再灌注损伤的效果及晚期糖基化终末产物受体(receptor for ad-vanced glycosylation end products,RAGE)在此过程中的作用。方法 12只健康犬依据主动脉开放后是否吸入七氟醚随机分为两组:对照组...目的探讨七氟醚后处理对犬体外循环肺缺血/再灌注损伤的效果及晚期糖基化终末产物受体(receptor for ad-vanced glycosylation end products,RAGE)在此过程中的作用。方法 12只健康犬依据主动脉开放后是否吸入七氟醚随机分为两组:对照组(control,n=6)在主动脉开放后常规机械通气和实验组(test,n=6)在主动脉开放后吸入1MAC七氟醚,持续10min。在开胸后即刻(T1)、主动脉开放90min实验结束前(T2)留取肺组织标本和肺静脉血标本。标检测肺组织湿干重比(wet/dry weight,W/D);比色法检测肺组织髓过氧化物酶活性(myeloperoxidase activity,MPO);光镜观察并盲法评分比较肺组织病理学变化;分别采取RT-PCR方法、Western blot检测肺组织RAGE的表达;酶联免疫吸附法检测血清白介素6(IL-6)和肿瘤坏死因子α(TNF-α)含量。结果两组相比,实验组肺组织W/D、MPO、肺损伤评分、RAGE基因表达和蛋白表达、IL-6和TNF-α含量在T2时较对照组降低(P<0.05);组内比较,所有指标实验结束时均较基础值明显升高(P<0.05)。结论七氟醚后处理对体外循环缺血/再灌注导致的肺损伤具有一定的保护作用,可能与其抑制RAGE合成与激活有关。展开更多
目的:观察针药并用对糖尿病肾病脾肾气虚挟痰瘀证患者氧化应激水平的影响。方法:116例糖尿病肾病脾肾气虚挟痰瘀证患者按照随机数字表法分为对照组和观察组各58例。对照组患者给予厄贝沙坦片口服,观察组给予针药综合疗法,1周为1个疗程,...目的:观察针药并用对糖尿病肾病脾肾气虚挟痰瘀证患者氧化应激水平的影响。方法:116例糖尿病肾病脾肾气虚挟痰瘀证患者按照随机数字表法分为对照组和观察组各58例。对照组患者给予厄贝沙坦片口服,观察组给予针药综合疗法,1周为1个疗程,两组均连续治疗8个疗程。比较两组患者临床疗效,观察患者治疗前后血糖、血脂及肾功能各指标水平变化,检测治疗前后患者血清超氧化物歧化酶(superoxide dismutase,SOD)、晚期糖基化终末产物(advanced glycosylation end products,AGE)、晚期氧化蛋白产物(advanced oxidation protein products,AOPP)、丙二醛(malondialdehyde,MDA)水平变化。结果:观察组的有效率为91.3%高于对照组的75.9%(χ2=5.098,P<0.05)。治疗后,观察组患者的血糖、血脂及肾功能改善优于对照组,其各指标水平显著低于对照组患者(P<0.05);观察组患者经治疗后SOD活性显著高于对照组患者,而AGE、AOPP、MDA水平则显著低于对照组患者(P<0.05)。结论:针药并用治疗糖尿病肾病患者疗效肯定,利于改善患者的糖脂代谢,提高肾功能,其机制与增强SOD活性、清除AGE、AOPP、MDA以减轻患者的氧化应激损伤有关。展开更多
文摘Erectile dysfunction （ED） is a major complication of diabetes mellitus. Icariin has been shown to enhance erectile function through its bioactive form, icarisid Ih This study investigates the effects of icarisid Ⅱ on diabetic rats with ED and its potential mechanism viathe assessment of advanced glycosylation end products （AGEs）, autophagy, mTOR and the NO-cGMP pathway. Icarisid Ⅱ was extracted from icariin by an enzymatic method. In the control and diabetic ED groups, rats were administered normal saline; in the icarisid Ⅱ group, rats were administered icarisid Ⅱ intragastrically. Erectile function was evaluated by measuring intracavernosal pressure/mean arterial pressure （ICP/MAP）. AGE concentrations, nitric oxide synthase （NOS） activity and cGMP concentration were assessed by enzyme immunoassay. Cell proliferation was analysed using methyl thiazolyl tetrazolium assay and flow cytometry. Autophagosomes were observed by transmission electron microscopy, monodansylcadaverine staining and GFP-LC3 Iocalisation. The expression of NOS isoforms and key proteins in autophagy were examined by western blot. Our results have shown that Icarisid Ⅱ increased ICP/MAP values, the smooth muscle cell （SMC） growth curve, S phase and SMC/collagen fibril （SMC/CF） proportions and decreased Beclin 1 （P〈0.05）. Icarisid Ⅱ significantly increased the proliferative index and p-p70S6K（Thr389） levels and decreased the numbers of autophagosomes and the levels of LC3-11 （P〈0.01）. Icarisid Ⅱ decreased AGE concentrations and increased cGMP concentration, NOS activity （P〈0.05） and cNOS levels （P〈0.01） in the diabetic ED group. Therefore, Icarisid Ⅱ constitutes a promising compound for diabetic ED and might be involved in the upregulation of SMC proliferation and the NO-cGMP pathway and the downregulation of AGEs, autophagy and the mTOR pathway.
文摘目的探讨七氟醚后处理对犬体外循环肺缺血/再灌注损伤的效果及晚期糖基化终末产物受体(receptor for ad-vanced glycosylation end products,RAGE)在此过程中的作用。方法 12只健康犬依据主动脉开放后是否吸入七氟醚随机分为两组:对照组(control,n=6)在主动脉开放后常规机械通气和实验组(test,n=6)在主动脉开放后吸入1MAC七氟醚,持续10min。在开胸后即刻(T1)、主动脉开放90min实验结束前(T2)留取肺组织标本和肺静脉血标本。标检测肺组织湿干重比(wet/dry weight,W/D);比色法检测肺组织髓过氧化物酶活性(myeloperoxidase activity,MPO);光镜观察并盲法评分比较肺组织病理学变化;分别采取RT-PCR方法、Western blot检测肺组织RAGE的表达;酶联免疫吸附法检测血清白介素6(IL-6)和肿瘤坏死因子α(TNF-α)含量。结果两组相比,实验组肺组织W/D、MPO、肺损伤评分、RAGE基因表达和蛋白表达、IL-6和TNF-α含量在T2时较对照组降低(P<0.05);组内比较,所有指标实验结束时均较基础值明显升高(P<0.05)。结论七氟醚后处理对体外循环缺血/再灌注导致的肺损伤具有一定的保护作用,可能与其抑制RAGE合成与激活有关。
文摘目的:观察针药并用对糖尿病肾病脾肾气虚挟痰瘀证患者氧化应激水平的影响。方法:116例糖尿病肾病脾肾气虚挟痰瘀证患者按照随机数字表法分为对照组和观察组各58例。对照组患者给予厄贝沙坦片口服,观察组给予针药综合疗法,1周为1个疗程,两组均连续治疗8个疗程。比较两组患者临床疗效,观察患者治疗前后血糖、血脂及肾功能各指标水平变化,检测治疗前后患者血清超氧化物歧化酶(superoxide dismutase,SOD)、晚期糖基化终末产物(advanced glycosylation end products,AGE)、晚期氧化蛋白产物(advanced oxidation protein products,AOPP)、丙二醛(malondialdehyde,MDA)水平变化。结果:观察组的有效率为91.3%高于对照组的75.9%(χ2=5.098,P<0.05)。治疗后,观察组患者的血糖、血脂及肾功能改善优于对照组,其各指标水平显著低于对照组患者(P<0.05);观察组患者经治疗后SOD活性显著高于对照组患者,而AGE、AOPP、MDA水平则显著低于对照组患者(P<0.05)。结论:针药并用治疗糖尿病肾病患者疗效肯定,利于改善患者的糖脂代谢,提高肾功能,其机制与增强SOD活性、清除AGE、AOPP、MDA以减轻患者的氧化应激损伤有关。
